WEST VIRGINIA LEGISLATURE 2024 REGULAR SESSION

Introduced

Senate Bill 586

By Senator Caputo

[Introduced January 29, 2024; referred

to the Committee on Health and Human Resources]

Intr SB 2024R3326

A BILL to amend the Code of West Virginia, 1931, as amended, by adding thereto a new section, designated §5-16-7h, relating to establishing an insulin safety net program.

Be it enacted by the Legislature of West Virginia:

ARTICLE 16. WEST VIRGINIA PUBLIC EMPLOYEES INSURANCE ACT.

§5-16-7h. Insulin Safety Net Program.

7

8

9

10

11

12

13

14

15

16

17

<u>4.</u>

- (a) By July 1, 2025, each manufacturer must establish procedures to make insulin
 available in accordance with this section to eligible individuals who are in urgent need of insulin
 or who are in need of access to an affordable insulin supply.
 (b) For purposes of this section, the following definitions apply: (1) "manufacturer" means
 a manufacturer engaged in the manufacturing of insulin that self-administered on an outpatient
 basis; (2) "pharmacy" means a pharmacy located in West Virginia, as defined by section §30-5-
 - (c) Any manufacturer with an annual gross revenue of \$2,000,000 or less from insulin sales in West Virginia is exempt from this section. To request a waiver under this paragraph, the manufacturer must submit a request to the Board of Pharmacy that includes documentation indicating that the manufacturer is eligible for an exemption.
 - (d) An insulin product is exempt from this section if the wholesale acquisition cost of the insulin is \$8 or less per milliliter or applicable National Council for Prescription Drug Plan billing unit, for the entire assessment time period, adjusted annually based on the consumer price index.
 - (e) Eligibility for urgent-need safety net program. To be eligible to receive an urgent-need supply of insulin under this section, an individual must attest to:
- 18 (1) Being a West Virginia resident.
- 19 (2) Not being enrolled in a medical assistance program.
- 20 (3) Not being enrolled in prescription drug coverage that limits the total amount of cost-21 sharing that the enrollee is required to pay for a 30-day supply of insulin, including co-payments,

Intr SB 2024R3326

22	deductibles, or coinsurance, to \$75 or less, regardless of the type or amount of insulin
23	prescribed.
24	(4) Not having received an urgent-need supply of insulin through this program within the
25	previous 12 months.
26	(5) Being in urgent need of insulin.
27	(6) For purposes of this subdivision, "urgent need of insulin" means having readily
28	available for use less than a seven-day supply of insulin and in need of insulin in order to avoid
29	the likelihood of suffering significant health consequences.
30	(f) To access to urgent-need insulin, the West Virginia Board of Pharmacy shall develop
31	an application form to be used by an individual who is in urgent need of insulin.
32	(1) The application must ask the individual to attest to the eligibility requirements
33	described in subsection (e).
34	(2) The form shall be accessible through the West Virginia Board of Pharmacy's website
35	and shall also be available to pharmacies and health care providers who prescribe or dispense
36	insulin, hospital emergency departments, urgent care clinics, and community health clinics.
37	(g) By submitting a completed, signed, and dated application to a pharmacy, the
38	individual attests that the information contained in the application is correct. If the individual is in
39	urgent need of insulin, the individual may present a completed, signed, and dated application
40	form to a pharmacy. The individual must also:
41	(1) Have a valid insulin prescription; and
42	(2) Present the pharmacist with identification indicating West Virginia residency in the
43	form of a valid West Virginia identification card, driver's license, or permit.
44	(3) If the individual in urgent need of insulin is under the age of 18, the individual's parent
45	or legal guardian must provide the pharmacist with proof of residency.
46	(h) Upon receipt of a completed and signed application, the pharmacist shall dispense
47	the prescribed insulin in an amount that will provide the individual with a 30-day supply. The

Intr SB 2024R3326

pharmacy must notify the health care practitioner who issued the prescription order no later than 72 hours after the insulin is dispensed.

- (i) The pharmacy may submit to the manufacturer of the dispensed insulin product or to the manufacturer's vendor a claim for payment that is in accordance with the National Council for Prescription Drug Program standards for electronic claims processing, unless the manufacturer agrees to send to the pharmacy a replacement supply of the same insulin as dispensed in the amount dispensed. If the pharmacy submits an electronic claim to the manufacturer or the manufacturer's vendor, the manufacturer or vendor shall reimburse the pharmacy in an amount that covers the pharmacy's acquisition cost.
- (j) The pharmacy may collect an insulin co-payment from the individual to cover the pharmacy's costs of processing and dispensing in an amount not to exceed \$35 for the 30-day supply of insulin dispensed.
- (k) The pharmacist shall retain a copy of the application form submitted by the individual to the pharmacy for reporting and auditing purposes.

NOTE: The purpose of this bill is to establish an insulin safety net program.

Strike-throughs indicate language that would be stricken from a heading or the present law and underscoring indicates new language that would be added.